SC 13G/A - AMAG PHARMACEUTICALS, INC. (0000792977) (Subject)
SC 13G/A - AMAG PHARMACEUTICALS, INC. (0000792977) (Subject)
SC 13G/A - AMAG PHARMACEUTICALS, INC. (0000792977) (Subject)
Company cofounder and CTO to lead button battery safety tech company toward commercialization The Directors of Landsdowne Labs, LLC, are pleased to announce the appointment of Bryan Laulicht to Chief Executive Officer. Laulicht, a company cofounder, has served as Lansdowne's Chief Technology Officer since the company's formation in 2017. He has also co-founded and served in leadership positions at two other companies focused on applying biophysics and bioengineering approaches to fulfilling unmet medical and safety needs. Both of those companies have been acquired for a combined total greater than $500M. Lansdowne's technology, applied to small, coin-like "button" batteries, is design
Regulatory News: Sensorion (PARIS:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces the appointment of Scott D. Myers as Chairman of its Board of Directors and Independent Director. Scott, who also serves as Chairman of the Board at Dynavax Technologies (NASDAQ:DVAX) and Harpoon Therapeutics (NASDAQ:HARP), brings almost 30 years of global experience in the pharmaceutical and medical technology industries to Sensorion. Previously, Mr Myers served as the Chief Executive Officer and Director of AMAG Pharmaceuticals, Inc (NASDAQ:AMAG), where h
WARREN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced the appointment of Julie Krop, M.D., Chief Medical Officer of Freeline Therapeutics (NASDAQ: FRLN), and Marco Taglietti, M.D., Director, President and Chief Executive Officer of SCYNEXIS (NASDAQ: SCYX), to the Board of Directors of the Company effective February 10, 2021. Aquestive also announced the resignation of Douglas K. Bratton from the Board of Directors after more than 17 years of service. Aquestive’s Board of Directors
Company cofounder and CTO to lead button battery safety tech company toward commercialization The Directors of Landsdowne Labs, LLC, are pleased to announce the appointment of Bryan Laulicht to Chief Executive Officer. Laulicht, a company cofounder, has served as Lansdowne's Chief Technology Officer since the company's formation in 2017. He has also co-founded and served in leadership positions at two other companies focused on applying biophysics and bioengineering approaches to fulfilling unmet medical and safety needs. Both of those companies have been acquired for a combined total greater than $500M. Lansdowne's technology, applied to small, coin-like "button" batteries, is design
Regulatory News: Sensorion (PARIS:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces the appointment of Scott D. Myers as Chairman of its Board of Directors and Independent Director. Scott, who also serves as Chairman of the Board at Dynavax Technologies (NASDAQ:DVAX) and Harpoon Therapeutics (NASDAQ:HARP), brings almost 30 years of global experience in the pharmaceutical and medical technology industries to Sensorion. Previously, Mr Myers served as the Chief Executive Officer and Director of AMAG Pharmaceuticals, Inc (NASDAQ:AMAG), where h
WARREN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced the appointment of Julie Krop, M.D., Chief Medical Officer of Freeline Therapeutics (NASDAQ: FRLN), and Marco Taglietti, M.D., Director, President and Chief Executive Officer of SCYNEXIS (NASDAQ: SCYX), to the Board of Directors of the Company effective February 10, 2021. Aquestive also announced the resignation of Douglas K. Bratton from the Board of Directors after more than 17 years of service. Aquestive’s Board of Directors